Self-driving laboratories: A paradigm shift in nanomedicine development

Area of Science:

• Drug Delivery and Nanotechnology
• Artificial Intelligence in Materials Science
• Pharmaceutical Development

Background:

• Nanomedicines have enabled successful therapeutics like mRNA COVID-19 vaccines, showcasing the potential of lipid nanoparticle technology.
• Despite successes, nanomedicine design and preclinical development are complex and time-consuming.
• Current methods lack efficiency in navigating the intricate preclinical landscape of nanomedicine formulations.

Purpose of the Study:

• To introduce the Nanomedicine Materials Acceleration Platform (NanoMAP) for streamlining nanomedicine preclinical development.
• To leverage artificial intelligence (AI) and high-throughput experimentation for accelerated nanomedicine design.
• To foster interdisciplinary collaboration and data sharing within the pharmaceutical science community.

Main Methods:

• Integration of high-throughput experimentation with advanced AI techniques, including active learning and few-shot learning.
• Development of a web-based application for centralized data sharing and collaborative research.
• Implementation of a data-driven design approach for nanomedicine formulations.

Main Results:

• NanoMAP is proposed as a platform to significantly expedite the preclinical development pipeline for nanomedicines.
• The platform facilitates efficient data curation and analysis, enabling faster iteration in nanomedicine design.
• It is expected to accelerate the creation of next-generation nanomedicines through a collaborative, data-intensive framework.

Conclusions:

• The proposed NanoMAP offers a transformative approach to nanomedicine development by integrating AI and high-throughput methods.
• This initiative aims to accelerate the discovery and optimization of novel nanomedicines.
• NanoMAP encourages broader participation in pharmaceutical data curation, advancing the field of drug delivery.